Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, gave a talk on “Patenting natural matters after Mayo and Myriad” at the 6th Annual Intellectual Property Seminar.
Our Past Events
Recommended Insights
From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China
21 October 2025As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as 'the Guidelines') included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to […]
Read more >
Breaking: China Released New Implementation Measures for the New Patent Linkage System
14 July 2021On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
Read more >
What is the difference between an Invention Patent and a Utility Model Patent?
13 August 2021There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]
Read more >
RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges
10 March 2025An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
Read more >